Npm1+/− heterozygous mice develop a haematological disorder with features resembling human myelodysplastic syndrome (MDS). Promoter hypermethylation of the NPM1 gene may lead to suppressed gene transcription and hence functional haploinsufficiency, which contributes to the development of MDS. Thirty-one patients with MDS and eight normal individuals were studied for promoter methylation and mRNA expression of NPM1. Methylation-specific PCR (MSP), COBRA and bisulfite sequencing were used to examine the NPM1 methylation status. Quantitative PCR was used to assess the expression of NPM1. NPM1 DNA methylation was rare, occurring in one of 31 cases as determined by MSP. There was no significant difference in NPM1 mRNA expression between MDS and normal blood samples. In conclusion, the finding suggests that NPM1 methylation is rare in MDS and does not play a major role in its pathogenesis.
- Myelodysplastic syndrome
- molecular oncology
Statistics from Altmetric.com
Y-Y C and DC contributed equally to this work.
Funding The project was supported by Small Project Funding (200807176120), University of Hong Kong.
Competing interests None.
Patient consent Obtained.
Ethics approval This study was conducted with the approval of the Queen Mary Hospital, University of Hong Kong.
Provenance and peer review Not commissioned; externally peer reviewed.